Thermogenic Biologicals for Obesity Treatment
Identification and use of novel adipokines for reduction of visceral fat using thermogenesis.
Obesity as a result of an increase in intra-abdominal (or visceral) fat is an independent risk factor for major diseases such as type 2 diabetes and cardiovascular diseases. Risk is increased with higher levels of intra-abdominal fat due to increases in insulin resistance and chronic inflammation, especially relative to subcutaneous fat. Accumulation of intra-abdominal fat, even in non-obese people, is strongly associated with all-cause mortality in people under 65 years of age. Reduction of abdominal fat improves health outcomes, but is extremely difficult to achieve. To reduce obesity, targeted therapies need to address not only the fat accumulation, but also the neurological pathways that regulate diet uptake and hormonal status. One avenue of exploration has been thermogenesis, however, to date, there are no specific therapies derived from thermogenic that target intra-abdominal obesity.
Researchers at The Ohio State University, led by Dr. Ouliana Ziouzenkova, identified neuroadipokines (e.g. GMFbeta) in intra-abdominal fat that support lipolysis and thermogenesis specifically in combination with thermogenic adipokines (EREG). They compared the effects of single and combined treatments with the neuro and thermoadipokines in a murine model. Compared to a single treatment, the combined treatment induced higher local heat production in the treated mice, reduce abdominal fat, as well as increased metabolic rate over longer period of time. A combinatory therapeutic derived from these adipokines could be used to reduce abdominal fat and lower obesity levels.